TOULOUSE, France – The U.S. right to try legislation signed by President Donald Trump on May 30 will embolden “bad actors” looking for ways to take advantage of vulnerable patients and make it easier for rogue clinics to evade regulation and sell unproven and scientifically dubious stem cell therapies, according to researchers speaking at the Euroscience Open Forum meeting this week.